KVD 818Alternative Names: KVD818
Latest Information Update: 24 Aug 2016
At a glance
- Originator KalVista Pharmaceuticals
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Plasma-kallikrein-inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hereditary angioedema